Regulatory Crackdown: FSSAI Suspends Tripura Water Unit’s Licence, Bans Punjab Dietary Supplement Over Severe Lapses

NEW DELHI — In a major enforcement drive aimed at safeguarding public health, India’s central food regulator, the Food Safety and Standards Authority of India (FSSAI), has suspended the operating licence of a packaged drinking water manufacturer in Tripura and prohibited the production, storage, distribution, and sale of a popular dietary supplement manufactured in Punjab. The twin regulatory actions, announced on August 3, 2026, follow inspections that revealed alarming hygiene breakdowns in drinking water processing and the unauthorized inclusion of active pharmaceutical ingredients in an over-the-counter wellness product.

The crackdown underscores a growing regulatory push across India to hold both hydration and nutraceutical manufacturers to strict safety, quality, and labeling standards as consumer reliance on packaged beverages and health supplements continues to rise.

Unhygienic Storage and Rusted Equipment: What Inspectors Found in Tripura

The first target of FSSAI’s enforcement action was M/S Matri Drinking Water, a packaged drinking water manufacturing unit located in Gomati, Tripura. Regulatory scrutiny was triggered after a consumer complaint raised alarms regarding foreign particulate matter found inside sealed bottles.

Subsequent surprise inspections by food safety officers revealed a cascade of critical sanitation failures and operational lapses throughout the facility:

• Contamination Risks: Finished water products were stored outdoors and directly on the facility floor alongside non-food materials.

• Substandard Infrastructure: Inspectors documented rusted Reverse Osmosis (RO) storage tanks and rusted chemical dosing containers, posing direct physical and chemical contamination risks.

• Lax Operations: Processing and filling zones lacked basic hygienic controls, pest control measures were inadequate, and the plant operated without a qualified technical supervisor on site.

• Missing Documentation: Mandatory testing logs, equipment maintenance schedules, and staff sanitation training records were either incomplete or non-existent.

Given the potential for widespread microbial and particulate contamination, FSSAI suspended the plant’s operating licence with immediate effect under Section 36(3)(b) of the Food Safety and Standards Act, 2006.

Crossing the Line from Supplement to Drug: The Case of Venolex Forte

In a separate action, the regulator issued a full prohibition order against M/S Noble Healthcare, based in Mohali, Punjab, regarding its marketed product Venolex Forte. Promoted as a “dietary food supplement,” the product was found to cross the line into pharmaceutical therapy.

According to official findings, Venolex Forte contained several potent, pharmacologically active ingredients:

• Calcium Dobesilate: A vasoactive prescription drug used primarily to treat microvascular disorders and chronic venous disease.

• Diosmin: A flavonoid glycoside used in prescription therapies for venous insufficiency and hemorrhoidal disease.

• Euphorbia prostrata: A botanical extract with significant anti-inflammatory and anti-hemorrhoidal properties.

None of these active medical substances are approved for inclusion in general dietary supplements under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations.

Furthermore, regulatory analysis revealed that Venolex Forte contained 90 mg of Vitamin C per serving. This level appears to exceed the Recommended Dietary Allowance (RDA) thresholds established under the Indian Council of Medical Research–National Institute of Nutrition (ICMR-NIN) 2020 guidelines for routine dietary supplementation.

Inspectors also cited the company for deceptive packaging. By prominently displaying an FSSAI licence number directly beneath the product name, the manufacturer created a misleading impression that the product had received special government endorsement or clinical validation as a therapeutic cure.

Public Health Context: Water Quality and Unregulated Nutraceuticals

Both enforcement actions target products that sit at the core of daily consumer habits and public trust.

Packaged Drinking Water Safety

Packaged drinking water is often consumed as a safe alternative to untreated tap water. World Health Organization (WHO) sanitation guidelines emphasize that water safety relies on continuous “source-to-tap” quality management. Biological contaminants like E. coli or Coliform bacteria, as well as heavy metals from rusted storage vessels, can cause acute gastrointestinal illnesses, localized outbreaks, and long-term toxicity. When maintenance records and technical oversight break down, product traceability becomes impossible, leaving consumers vulnerable.

The Hidden Risks of OTC Supplements

The supplement sector presents a different, often subtler health risk. When a dietary product contains undisclosed active drug ingredients, consumers may unknowingly expose themselves to adverse drug interactions, organ toxicity, or unexpected drop in blood pressure. Calcium Dobesilate and synthetic flavonoids, while beneficial under medical supervision, require diagnostic evaluation and dosage monitoring.

Expert Commentary: Protecting the Consumer Safety Net

Medical professionals emphasize that regulatory enforcement is essential for preserving the line between nutrition and clinical therapy.

“Consumers routinely trust bottled water to be clean and supplements to be benign,” says Dr. Anil Kumar, a Delhi-based clinical nutrition specialist not involved in the case. “When water processing facilities ignore basic hygiene, or when supplement makers slip prescription-strength drug compounds into over-the-counter pills, the public health safety net is compromised.”

Dr. Kumar notes that wellness marketing often lulls buyers into a false sense of security:

“A product labeled as a ‘natural’ or ‘dietary’ supplement is not inherently safe for everyone. Ingredients that alter vascular tone or blood clotting can interact dangerously with prescription medications. That is why strict regulatory boundaries are vital—especially for vulnerable populations like pregnant women, the elderly, or patients with chronic cardiovascular conditions.”

Limitations and Regulatory Scope

While these regulatory orders highlight important safety concerns, certain analytical limitations should be kept in mind:

1. Regulatory Action vs. Clinical Harm: A suspension or prohibition order indicates non-compliance with legal statutes and safety standards; it does not automatically imply that clinical harm or acute poisoning has been documented in specific patients.

2. Preliminary Reports: Public statements from the regulator summarize inspection observations; complete laboratory assay data and formal responses from M/S Matri Drinking Water or M/S Noble Healthcare have not yet been fully released in public health repositories.

3. Preventive Nature: Regulatory bans act primarily as preventive measures to eliminate risk before widespread clinical harm occurs.

What Consumers Should Do

To protect personal and family health, experts recommend several practical guidelines:

• Inspect Packaged Water: Buy only from recognized, licensed brands. Examine bottles for intact tamper-evident seals, clear batch coding, and visible floating particles before purchase.

• Scrutinize Supplement Labels: Look for the full ingredient declaration and serving sizes. Be cautious of products claiming to treat, cure, or manage chronic medical conditions like varicose veins, joint pain, or diabetes.

• Consult Healthcare Professionals: Before starting any high-potency nutraceutical or multi-ingredient dietary supplement, review the formula with a primary physician or clinical nutritionist—particularly if taking prescription drugs.

• Report Lapses: Use official food safety portals (such as FSSAI’s Food Safety Connect) to report suspicious taste, foreign particles, or misleading medical claims on food products.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Food Safety and Standards Authority of India (FSSAI). Public enforcement order against M/S Matri Drinking Water and M/S Noble Healthcare under Section 36(3)(b) of the FSS Act, 2006. Issued August 3, 2026.